ALKS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alkermes Plc (ALKS) is currently not a strong buy for a beginner investor with a long-term strategy. While the stock shows some positive catalysts, such as progress in clinical trials and orphan drug designations, the lack of significant trading signals, neutral insider and hedge fund sentiment, and mixed technical indicators suggest that this is not the optimal entry point for investment. The stock may be worth monitoring for better opportunities.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 71.822, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are Pivot: 44.001, R1: 45.365, S1: 42.638, R2: 46.207, S2: 41.795. The stock shows a 70% chance to increase 1.13% in the next day, 4.81% in the next week, and 7.26% in the next month.
Alkermes' alixorexton achieved positive Phase 2 results in narcolepsy type 2, meeting primary endpoints with significant improvements in wakefulness and safety. The company received orphan drug designations from the FDA and European Commission for alixorexton, enhancing its position in the sleep medicine market.
The MACD indicates bearish momentum, and there is no significant hedge fund or insider trading activity. Analysts' ratings are mixed, with some maintaining neutral stances and others raising price targets modestly.
No financial data available for analysis.
Analysts are mixed on Alkermes. While some firms like Needham and UBS have raised price targets to $50 and $48, respectively, others like H.C. Wainwright maintain a Neutral rating with a $43 price target. The stock is seen as undervalued by some analysts but lacks unanimous bullish sentiment.
